tablets Belara are shown for hormonal contraception.

Structure

Active ingredients: 1 tablet, coated, supports a chlormadinon of acetate of 2 mg, ethinylestradiol of 0.03 mg;

Excipients: lactose, starch corn, K-30, magnesium stearate;

Cover: gipromelloza, lactose, titan dioxide (E 171), talc, polyethyleneglycol (macrogoal 6000), propylene glycol, ferrous oxide red (E 172).

Contraindication

• Hypersensitivity to active ingredients or to any other component of medicine.
• Loss of control over diabetes.
• Uncontrollable arterial hypertension or substantial increase of arterial blood pressure (the value is constantly exceeded by 140/90 mm Hg.).
• Existence or risk of developing of a venous thrombembolia (VTE).
• Existence or risk of developing of an arterial thrombembolia (ATE).
• Hepatitis, jaundice, an abnormal liver function (before normalization of indicators of function of a liver).
• Generalized itch, a cholestasia, in particular during the previous pregnancy or therapy by estrogen.
• Syndrome Cudgel Johnson, Rotor syndrome, biliation violation.
• Tumour of a liver in the anamnesis or now.
• Severe pain in epigastriums, increase in a liver or symptoms of intra belly bleeding.
• Porphyria which arose for the first time or recuring (all three forms, especially acquired porphyria).
• Malignant hormonedependent tumors in the anamnesis or now, for example tumors of mammary glands or a uterus.
• Heavy violations of lipid metabolism.
• Pancreatitis in the anamnesis or now that is followed by a heavy gipertriglitseridemiya.
• migraine Symptoms which arose for the first time and also frequent and very severe headache.
• Acute touch frustration, for example disorder of vision or hearing.
• Motive violations (in particular paresis).
• Strengthening of epileptic seizures.
• Heavy depression.
• Otosclerosis that progressed during the previous pregnancies.
• Amenorrhea of the obscure etiology.
• endometrium Hyperplasia.
• Bleeding from a vagina of the obscure etiology.
• Simultaneous application with the medicines containing ombitasvir/paritaprevir/ritonavir and dazabuvir.

Route of administration

1 tablet, coated, it is necessary to accept daily at the same time (mainly in the evening) within 21 days in a row, then it is necessary to take a seven-day break in reception of tablets; in 2-4 days after reception of the last tablet, coated, there will be cancellation bleeding, similar menstrual bleeding. After the termination of a seven-day break it is necessary to begin administration of medicament of Belara® from the following packing irrespective of, bleeding stopped or not.

Tablet, the coated, noticed on packing in the corresponding afternoon ​​ weeks, it is necessary to take from the blister packing and to swallow entirely, if necessary having washed down with a small amount of water. Tablets, film coated, it is necessary to accept daily in the sequence specified on packing by the direction of an arrow.

Feature of application

Pregnant

It is contraindicated.

Children

not to use Drug to children.

Overdose

Information about serious toxic effect of medicine at overdose is absent. The following symptoms can be observed: nausea, vomiting, and - especially at young girls are insignificant bloody discharges from a vagina. There is no specific antidote; to carry out symptomatic therapy. Control of indicators of water and electrolytic exchange and function of a liver can be in rare instances necessary.

Side effects

Clinical trials of the tableted forms with the same combination of active agents showed that the most frequent side effects (> 20%) were breakthrough bleeding, insignificant bloody discharges, a headache and discomfort in a breast. Probability of irregular bleedings decreases at continuation of reception of tablets with the same composition of active ingredients.

Interaction

Note: for identification of possible types of interaction it is necessary to study instructions for use of the medicaments taken along with this medicine.

Contraindicated simultaneous application with the medicines containing ombitasvir/paritaprevir/ritonavir and dazabuvir.

to Store

at a temperature not above 25 °C.

to Store

out of children's reach!

Expiration date - 3 years.